Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM)

Regional University Hospital Center (CHRU)

Status: Active, not recruiting

Conditions: Myeloproliferative Disorders

Study type: Observational

Funder types: Other

Identifiers

NCT06481345

29BRC24.0154 - CARPEDIEM

Details and patient eligibility

About

Retrospective study assessing the impact of IDH1/2, SRSF2 or SF3B1 mutations on event free survival of MPN patients

Full description

Patients with a diagnosis of MPN and a mutation of IDH1/2, SRSF2 or SF3B1 will be included. Clinical and biological characterisation at diagnosis, as well as evlution will be recorded. Event free survival will be assessed in each group (event = thrombosis, transformation to mylofibrosis/acute leukemia, death).

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with MPN diagnosis
• Mutation in IDH1/2, SRSF2 or SF3B1

Exclusion criteria

• Unable to consent

Trial design

300 participants in 3 patient groups

MPN patients with IDH1/2 mutation

MPN patients with SRSF2 mutation

MPN patients with SF3B1 mutation